<DOC>
	<DOCNO>NCT00025623</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug , give surgery , may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow surgery treating infant newly diagnose neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Treating Infants With Newly Diagnosed Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Confirm management infant newly diagnose stage IV neuroblastoma without MYCN amplification treat etoposide carboplatin cyclophosphamide , doxorubicin , vincristine follow surgery require intensive high-dose chemotherapy consolidation . - Determine whether deletion chromosome 1p diploidy/tetraploidy prognostic factor patient . - Determine whether prognostic criterion could use future therapeutic stratification patient . OUTLINE : This multicenter study . Patients receive VP-CARBO chemotherapy comprise etoposide IV 2 hour carboplatin IV 1 hour day 1-3 . Treatment repeat every 21 day 2 course . Patients without disease progression receive 2 additional course VP-CARBO chemotherapy . Patients metastatic complete response ( CR ) undergo surgical resection primary disease . Patients disease progression 2 4 course VP-CARBO chemotherapy receive CADO chemotherapy comprise cyclophosphamide IV 1 hour day 1-5 , doxorubicin IV 6 hour day 4 5 , vincristine IV day 1 5 . Treatment repeat every 21 day 2 course . After 2 course CADO chemotherapy , patient metastatic CR undergo surgical resection primary disease . Patients residual disease receive 2 additional course CADO chemotherapy . Patients residual disease 4 course CADO chemotherapy remove study . Patients metastatic CR additional CADO chemotherapy undergo surgical resection primary disease . Patients follow within 6 month annually 5 year . PROJECTED ACCRUAL : A total 60 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose stage IV neuroblastoma ganglioneuroblastoma Metastases bone , CNS , pleura/lung xray CT scan No MYCN amplification ( i.e. , few 10 copy ) PATIENT CHARACTERISTICS : Age : Under 12 month diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>